Ensoma
Ensoma disclosed mouse proof of concept for in vivo HSC engineering that generates CAR-bearing macrophage, NK, and T-cell lineages. This is an HSC-derived, multi-lineage approach, distinct from directly transducing mature T cells. CAR-T human efficacy is not established.
Corporate information
- Company entity
- Ensoma
- Headquarters / principal office
- Boston, MASelf-reported location on the company LinkedIn page; regional scope may differ from the legal or global headquarters. ↗
- Founded
- Not verified
- Ownership / capital status
- PrivatePrivately financed biotechnology company ↗
- Official corporate reference
- https://ensoma.com/ ↗
- LinkedIn company page
- LinkedIn ↗ ↗
- Latest financing / award identified
- 2025-09-22 · Financing; round name not disclosed · US$53 million ↗
A verified disclosed financing, not a claim that no later financing exists. The release does not name a lettered round; EN-374 trial funding is distinct from CAR-T clinical validation.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Start with public sources and capability boundaries; company claims are not independent certification.
Ask AI ↗Public evidence snapshot
Ensoma disclosed mouse proof of concept for in vivo HSC engineering that generates CAR-bearing macrophage, NK, and T-cell lineages. This is an HSC-derived, multi-lineage approach, distinct from directly transducing mature T cells. CAR-T human efficacy is not established.
This profile is a research snapshot, not a company endorsement. Check original sources for current information.
Original sources
- Ensoma — primary program / ownership disclosure
- Ensoma — official company page
- Ensoma $53 million financing — September 22, 2025
- Company-managed LinkedIn profile — self-reported location